This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - treatments for COPD (chronic obstructive pulmonary disease) - OSAHS (obstructive sleep apnoea/hypopnoea syndrome) overlap syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Lifestyle advice for COPD (chronic obstructive pulmonary disease)-OSAHS (obstructive sleep apnoea/hypopnoea syndrome) overlap syndrome

explain to people with mild COPD-OSAHS who have no symptoms or with symptoms that do not affect usual daytime activities that:

  • treatment is not usually needed and
  • changes to lifestyle and sleep habits can help to prevent COPD-OSAHS from worsening
    • lifestyle advice for all severities of COPD-OSAHS
      • discuss appropriate lifestyle changes with all people with COPD-OSAHS. Provide support and information on losing weight, stopping smoking, reducing alcohol intake and improving sleep hygiene, tailored to the person's needs and in line with the NICE guidelines on:
        • stop smoking interventions and services
        • preventing excess weight gain
        • obesity: identification, assessment and management (in particular, the section on lifestyle interventions)
        • alcohol-use disorders: prevention (in particular, recommendations on screening, brief advice and extended brief interventions for adults)

Treatments for COPD (chronic obstructive pulmonary disease)-OSAHS (obstructive sleep apnoea/hypopnoea syndrome) overlap syndrome

CPAP and non-invasive ventilation

  • consider continuous positive airway pressure (CPAP) as first-line treatment for people with COPD-OSAHS overlap syndrome if they do not have severe hypercapnia (PaCO2 of 7.0 kPa or less)
  • consider non-invasive ventilation instead of CPAP for people with COPD–OSAHS overlap syndrome with nocturnal hypoventilation if they have severe hypercapnia (PaCO2 greater than 7.0 kPa)
  • consider heated humidification in addition to CPAP for people with COPD–OSAHS overlap syndrome and upper airway side effects such as nasal and mouth dryness, and CPAP-induced rhinitis

Oxygen therapy

  • consider supplemental oxygen for people with COPD-OSAHS overlap syndrome if hypoxaemia persists once control of apnoea and nocturnal hypoventilation has been optimised by CPAP or non-invasive ventilation, and address any additional underlying causes of hypoxaemia where possible

Managing rhinitis in people with COPD (chronic obstructive pulmonary disease)-OSAHS (obstructive sleep apnoea/hypopnoea syndrome) overlap syndrome

  • assess people with nasal congestion and COPD-OSAHS for underlying allergic or vasomotor rhinitis
  • if rhinitis is diagnosed in people with COPD-OSAHS, offer initial treatment with:
    • topical nasal corticosteroids or antihistamines for allergic rhinitis or
    • topical nasal corticosteroids for vasomotor rhinitis
  • for people with COPD-OSAHS and persistent rhinitis, consider referral to an ear, nose and throat specialist if:
    • symptoms do not improve with initial treatment or
    • anatomical obstruction is suspected
  • be aware that:
    • rhinitis can affect people's tolerance to continuous positive airway pressure (CPAP) but changing from a nasal to an orofacial mask and adding humidification can help
    • CPAP can worsen or cause rhinitis and nasal congestion

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.